Search by Drug Name or NDC
NDC 31722-0759-05 CLOPIDOGREL 300 mg/1 Details
CLOPIDOGREL 300 mg/1
CLOPIDOGREL is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Camber Pharmaceuticals, Inc.. The primary component is CLOPIDOGREL.
MedlinePlus Drug Summary
Clopidogrel is used alone or with aspirin to prevent serious or life-threatening problems with the heart and blood vessels in people who have had a stroke, heart attack, or severe chest pain. This includes people who have percutaneous coronary intervention (PCI; angioplasty; a type of heart surgery) that may involve inserting coronary stents (metal tubes surgically placed in clogged blood vessels to improve blood flow) or who have coronary artery bypass grafting (CABG; a type of heart surgery). Clopidogrel is also used to prevent serious or life-threatening problems with the heart and blood vessels in people who have peripheral arterial disease (poor circulation in the blood vessels that supply blood to the legs). Clopidogrel is in a class of medications called antiplatelet medications. It works by preventing platelets (a type of blood cell) from collecting and forming clots that may cause a heart attack or stroke.
Related Packages: 31722-0759-05Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Clopidogrel
Product Information
| NDC | 31722-0759 |
|---|---|
| Product ID | 31722-759_04d99965-cea0-8e7d-e063-6394a90ab281 |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | CLOPIDOGREL |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | CLOPIDOGREL |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 300 |
| Active Ingredient Units | mg/1 |
| Substance Name | CLOPIDOGREL |
| Labeler Name | Camber Pharmaceuticals, Inc. |
| Pharmaceutical Class | Cytochrome P450 2C8 Inhibitors [MoA], Decreased Platelet Aggregation [PE], P2Y12 Platelet Inhibitor [EPC], P2Y12 Receptor Antagonists [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA205345 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 31722-0759-05 (31722075905)
| NDC Package Code | 31722-759-05 |
|---|---|
| Billing NDC | 31722075905 |
| Package | 500 TABLET in 1 BOTTLE (31722-759-05) |
| Marketing Start Date | 2023-08-04 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |